Abstracts tagged "Economics"

Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Eiichi Tanaka¹, Eisuke Inoue², Yoko Shimizu³, Akiko Kobayashi², Naoki Sugimoto², Daisuke Hoshi², Kumi Shidara², Eri Sato³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…
Abstract Number: 1830 • 2012 ACR/ARHP Annual Meeting
Drugs Are the Major Cost Driver of Rheumatoid Arthritis As Soon As the First Year of the Disease: An Economic Analysis Based On the Espoir Cohort Data
Bruno Fautrel¹, Sandy Lucier², Georges Haour², Hassani Maoulida², Stephanie Harvard¹, Alain Saraux³, Xavier Mariette⁴, Francis Guillemin⁵, Isabelle Durand-Zaleski² and Karine Chevreul², ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²APHP - URC Eco, Paris, France, ³Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁵Hopitaux de Brabois, Nancy, France
Background/Purpose: Many studies have explored the economic burden of established RA but few data are available about the determinants of costs in early rheumatoid arthritis…
Abstract Number: 1831 • 2012 ACR/ARHP Annual Meeting
Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database
Eiichi Tanaka¹, Eisuke Inoue², Daisuke Hoshi³, Akiko Kobayashi², Naoki Sugimoto², Kumi Shidara², Eri Sato³, Yasushi Inoue³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara³, Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disorder, causes a significant decrease in quality of life. Recently developed biologic agents (BAs) have caused a considerable…
Abstract Number: 1833 • 2012 ACR/ARHP Annual Meeting
Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate
Frank Zhang¹, Robert Hiscock² and Jeffrey R. Curtis³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²Analysis Group, Inc., Montreal, QC, Canada, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). The healthcare cost associated with the management of PsA pts varies depending on…
Abstract Number: 1812 • 2012 ACR/ARHP Annual Meeting
A Retrospective Evaluation of the Clinical and Economic Implications of Gout in Nursing Home Residents in Hawaii Treated with Allopurinol
Joy Higa¹, Gregory Reardon² and Gregory Tong³, ¹Long Term Care Research Center, Kaneohe, HI, ²Informagenics, LLC, Worthington, OH, ³Takeda Pharmaceuticals America, Inc., Deerfield, IL
Background/Purpose: We describe patient characteristics, serum uric acid (sUA) levels while on allopurinol, and activities of daily living (ADL) in nursing home residents with gout.…
Abstract Number: 1815 • 2012 ACR/ARHP Annual Meeting
Factors Associated with a Prolonged Hospital Length of Stay for Patients with Acute Gout
Rebecca Sharim¹, Meghan Musselman² and Marissa Blum³, ¹Department of Medicine, Temple University Hospital, Philadelphia, PA, ²Temple University School of Medicine, Philadelphia, PA, ³Medicine/Rheumatology, Temple University School of Medicine, Philadelphia, PA
Background/Purpose: Management of gout in the hospital setting has been poor. This study aimed to describe patient characteristics and the treatment patterns of acute gout…
Abstract Number: 1816 • 2012 ACR/ARHP Annual Meeting
Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout
Kim Coley¹, Melissa Saul² and Karen Pater¹, ¹Pharmacy & Therapeutics, University of Pittsburgh, Pittsburgh, PA, ²Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gout is a chronic inflammatory disease caused by the deposition of monosodium urate crystals in joints and soft tissues. The overall prevalence is increasing…
Abstract Number: 918 • 2012 ACR/ARHP Annual Meeting
Impact of Comorbidities On Measuring Indirect Utility by the Medical Outcomes Study Short Form 6D in Lower-Limb Osteoarthritis
Kossar Hosseini¹, Cécile Gaujoux-Viala², Joel Coste³, Jacques Pouchot¹, Bruno Fautrel⁴, Anne-Christine Rat⁵ and Francis Guillemin¹, ¹Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, F- 54 000, France, Nancy, France, ²Rheumatology, Montpellier I University, Nîmes University Hospital, Nîmes, France, ³Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴Rheumatology, UPMC - Paris 6 University, Paris, France, ⁵Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France
Background/Purpose: Comorbidities refer to chronic co-occuring disorders and are inversely and negatively correlated with HRQoL. Because indirect utility measurement involves HRQoL, comorbidities probably affect utility…
Abstract Number: 910 • 2012 ACR/ARHP Annual Meeting
The Cost-Effectiveness of Total Joint Arthroplasty: A Systematic Review of Published Literature
Meghan E. Daigle¹, Alexander M. Weinstein¹, Jeffrey N. Katz² and Elena Losina¹, ¹Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ²Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Utilization of total hip arthroplasty (THA) and total knee arthroplasty (TKA) has nearly doubled in the last decade. These procedures are increasingly performed in…
Abstract Number: 717 • 2012 ACR/ARHP Annual Meeting
Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative
Lesley Ann Saketkoo¹, Reuben Escorpizo², Kevin J. Keen³, Kim Fligelstone⁴ and Oliver Distler⁵, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications in Germany (DIMDI), Nottwil, Switzerland, ³Mathematics and Statistics, University of Northern British Columbia, Prince George, BC, Canada, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Systemic Sclerosis (SSc) affects multiple organs with complex combinations of disability. Skin fibrosis, ischemic pain, ulceration, arthritis, joint contractures, myopathy and cardiopulmonary, renal as…
Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Vernon F. Schabert¹, Crystal Watson², George Joseph², Paige Iversen¹, Chakkarin Burudpakdee¹ and David J. Harrison², ¹IMS Health, Alexandria, VA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…
Abstract Number: 270 • 2012 ACR/ARHP Annual Meeting
Use of Drug Combinations in Patients with Osteoarthritis: A Population-Based Cohort Study
Daniel Prieto-Alhambra¹ and Rosa Morros², ¹Internal Medicine; Primary Care; NDORMS Dept; MRC Lifecourse Epidemiology Unit, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, ²Primary Care, IDIAP Jordi Gol; Institut Català de la Salut, Spain
TITLE: "Use of drug combinations in patients with osteoarthritis: a population-based cohort study."Background/Purpose: Patients affected with osteoarthritis (OA) use different drugs in search for relief.…
Abstract Number: 60 • 2012 ACR/ARHP Annual Meeting
The Burden of Early Arthritis in Latin America: Utility Analysis Using Patient-Level Data From the Argentinian Consortium for Early Arthritis
Christian A. Waimann¹, Gustavo Citera², Hernan Maldonado Ficco³, Oscar L. Rillo⁴, Mariana Benegas⁵, Rafael Chaparro del Moral⁶, Antonio Catalan Pellet⁷, Anastasia Secco⁸, Lucila Marino⁹, Alberto Berman¹⁰, Horacio Berman¹⁰, Ana Lucía Barbaglia¹¹, Juan Carlos Marcos¹², Josefina Marcos¹³, Francisco Caeiro¹⁴, Maria Haye Salinas¹⁵, Ana C. Alvarez¹⁶, Enrique Soriano¹⁷, Zaida Bedran¹⁸, Sergio Paira¹⁹, Federico Ceccato¹⁹, Gabriela Salvatierra²⁰, Ana Quinteros²¹, Emilio Buschiazzo²² and Edson Javier Velozo²³, ¹Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁴Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁵Rheumatology, Hospital Tornu, Buenos Aires, Argentina, ⁶Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁷Rheumatology, Hospital Rivadavia, Buenos Aires, Argentina, ⁸Rheumathology, Hospital Bernardino Rivadavia, Buenos aires, Argentina, ⁹Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ¹⁰Centro Medico Privado de Reumatologia, Tucuman, Argentina, ¹¹Rheumatology, Hospital Padilla, Tucuman, Argentina, ¹²Rheumatology, Hospital San Martin, La Plata, Argentina, ¹³Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ¹⁴Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ¹⁵Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ¹⁶Rheumatology, Hospital Privado, Córdoba, Argentina, ¹⁷Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁸Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁹Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ²⁰Rheumatology, Centro de enfermedades Reumaticas, Santiago Del Estero, Argentina, ²¹Centro Integral de Reumatología, Tucumán, Argentina, ²²Rheumatology, Hospital Señor del Milagro, Salta, Argentina, ²³Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina
Background/Purpose: Rheumatoid arthritis (RA) is estimated to be one of the leading causes of non-fatal burden in the world. However, data from developing countries including…
Abstract Number: 2509 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Training Rural Providers to Perform Joint Injections
Michael J. Battistone¹, Richard E. Nelson², William D. Ashworth³, Andrea Barker³, Marissa Grotzke⁴, Timothy A. Huhtala⁵, Robert Z. Tashjian⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Division of Epidemiology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ³General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁴Division of Endocrinology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁵Division of General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Division of Orthopaedics, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Community based outpatient clinics (CBOCs) have been established by the Department of Veteran Affairs (VA) to provide primary care services to veterans living in…
Abstract Number: 2646 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tai Chi Mind-Body Exercise for the Treatment of Fibromyalgia
John B. Wong¹ and Chenchen Wang², ¹Medicine/Clinical Decision Making, Tufts Medical Center, Boston, MA, ²Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Although fibromyalgia is associated with substantial annual direct medical and indirect productivity costs, the cost-effectiveness of treatments for fibromyalgia remains understudied. A randomized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].